Another Near Miss For Zynerba's Cannabidiol Gel
Executive Summary
Zynerba's gel formulation of cannabidiol has failed to hit the primary endpoint in a second Phase II study in as many weeks, but the company maintains that there is a way forward.
You may also be interested in...
Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
Commercial Capsules: BMS's Opdivo Knock; Novo Nordisk Vs Eli Lilly; Roivant Raises; Sun Plunges; Other R&D Stumbles
Bristol-Myers Squibb faces a second clinical disappointment with Opdivo/Yervoy, allowing Exelixis to take advantage; Novo Nordisk claims a victory over Eli Lilly in the GLP-1 space; Roivant Sciences closed a $1.1bn equity financing; India’s biggest drug firm, Sun Pharma, slid into the red; Regeneron drops out of RSV; and Zynerba's cannabidiol gel misses again. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
Travere’s Filspari US Approval Marks First For IgAN
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.